Alliance for Pharmacy Compounding

Alliance for Pharmacy Compounding We're the voice for pharmacy compounding and the advocate for thousands of pharmacy compounding profe

Great deal: $20 for CE and a game planApril 30 is almost here, and if you haven't registered yet for Stronger Together –...
04/28/2026

Great deal: $20 for CE and a game plan

April 30 is almost here, and if you haven't registered yet for Stronger Together – Collaborative Approaches to Advocacy and Practice Advancement, this is your reminder. Dr. Jenny Arnold, Dr. Dawn Ipsen, and Dedi Little, the founding leaders of Washington State's Compounding SIG, will walk through how they built their state advocacy operation from the ground up and how you can replicate it in your state. The CE credit is $20 (for both pharmacists and technicians), and with everything happening in state legislatures right now, the timing couldn't be more relevant.

Don’t miss your chance to register.
https://bit.ly/4d9L6D5

A patient nearly lost their life after taking a compounded weight-loss drug.That demands attention. It demands investiga...
04/27/2026

A patient nearly lost their life after taking a compounded weight-loss drug.

That demands attention. It demands investigation. And most importantly:
It demands accuracy.

The Washington Post article highlights risks tied to products that may include:
- Unregulated ingredient sourcing
- Unapproved drug combinations
- Lack of FDA evaluation for safety and efficacy

These are serious concerns.

But we cannot lose sight of this:
Not all compounding is the same.

Licensed pharmacies and FDA-registered outsourcing facilities operate under defined standards to safely meet patient needs every day.

When we blur that distinction, we risk:
- Misleading patients
- Undermining trust
- Creating policy that misses the real issue

Patients deserve transparency. Providers deserve clarity.

And when harm occurs, we owe everyone evidence-based answers, not assumptions.

Read APC CEO Scott Brunner’s response here:
https://bit.ly/49dluml

A balanced take on peptides. As the peptide debate heats up, CNN's Jacqueline Howard offers one of the more even-handed ...
04/24/2026

A balanced take on peptides. As the peptide debate heats up, CNN's Jacqueline Howard offers one of the more even-handed pieces we've seen on the topic, largely because she spoke with clinicians who actually prescribe peptides, not just critics of compounding. The core argument compounders have been making all along – that a regulated pathway is safer than the current gray market – gets a fair hearing here. Worth sharing with patients and prescribers trying to make sense of the moment.
https://cnn.it/4twxabZ

Your next prescription could be a walk in the park. Axios reports on the quiet rise of “social prescribing,” a growing movement where physicians are opting to refer patients to walking clubs, art studios, and nature activities alongside traditional treatment. The U.K.’s NHS has logged more than 5.5 million such referrals in five years, and while the evidence base is still developing, the premise is hard to argue with: sometimes what a patient needs most isn’t just a pill. If that resonates, remember that APC members can access Dr. Hetterly's Owner Summit session on burnout – it covers a lot of the same ground.
https://bit.ly/3R0x5ik

04/23/2026

At a time when policy debates, drug shortages, and market shifts continue to redefine healthcare delivery, our new Snapshot of Pharmacy Compounding in America provides something essential: clear, industry-grounded insight from the compounding pharmacists and pharmacies doing the work every day.

Check out the Snapshot to learn more interesting facts about the work compounders are doing.

https://bit.ly/4e3W8e1

Join us April 30 for Stronger Together – Collaborative Approaches to Advocacy and Practice Advancement. The speakers kno...
04/22/2026

Join us April 30 for Stronger Together – Collaborative Approaches to Advocacy and Practice Advancement. The speakers know the subject firsthand: Dr. Jenny Arnold, CEO of the Washington State Pharmacy Association, has spent more than 15 years advancing pharmacy advocacy in the state. Dr. Dawn Ipsen is a practicing compounding pharmacist, APC board member, and founding chair of WSPA's Compounding SIG. Dedi Little brings more than 35 years of lobbying experience in Olympia. Together, they'll walk through how Washington built its advocacy infrastructure and how you can apply the same approach in your state. The CE credit is $20. Register here.

https://bit.ly/3OGcyiv

The Department of Health and Human Services' Office of Inspector General, the federal agency responsible for independent...
04/21/2026

The Department of Health and Human Services' Office of Inspector General, the federal agency responsible for independently auditing HHS programs, announced a new study last week examining how well the FDA has been overseeing the compounding of GLP-1 drugs.

The focus: how frequently FDA inspects compounding facilities and how effectively it uses available data to identify patient safety risks.

The backdrop is the 2022–2025 GLP-1 drug shortages, which legally allowed compounding facilities to produce copies of those drugs – and the question of whether some facilities are still compounding at scale now that those shortages have ended.

The project has an estimated completion date of fiscal year 2028, which tells you something about the scope. For legitimate, compliant compounding pharmacies, a rigorous federal review isn't something to fear – it's an opportunity to demonstrate that the regulated system works exactly as it should, and that bad actors operating outside it are the real problem worth investigating.

https://bit.ly/3ODYiH0

We talk a lot about the importance of compounding, but now we’re finally putting real data behind it. APC’s data project...
04/21/2026

We talk a lot about the importance of compounding, but now we’re finally putting real data behind it. APC’s data project is all about showing, with actual numbers, how compounding is being used across the country and why it matters for patient care.

If you’ve ever wished we had better answers when regulators or legislators ask “how often is this really happening?” — this is how we get there.

Participation is simple, de-identified, and makes a real difference. Learn more and get involved: APC Data Cover Sheet

https://bit.ly/41MC1Ka

When a patient is harmed, we owe them answers, not assumptions.A recent Washington Post opinion highlights a serious pat...
04/20/2026

When a patient is harmed, we owe them answers, not assumptions.

A recent Washington Post opinion highlights a serious patient safety event involving a compounded GLP-1 medication. The story is tragic, and it deserves attention.

But it also raises an important question:
Are we focusing on the right problem?

Compounding exists to serve patients with legitimate medical needs, including customized dosing, allergen-free formulations, and access when no commercial option fits. It is a regulated, essential part of healthcare.

At the same time, as demand for weight-loss drugs surges, a separate and growing concern has emerged: unapproved, mass-produced copycat products operating outside appropriate safeguards.

Those are not the same thing.

If we want to protect patients, we must be clear:
- Bad actors should be addressed
- Unsafe practices should be stopped
- But compounding itself should not be misunderstood or misrepresented

The word “imminent” has been attached to FDA action on peptides for more than a year now, but a newly announced meeting ...
04/20/2026

The word “imminent” has been attached to FDA action on peptides for more than a year now, but a newly announced meeting has resparked that urgency among our media friends, and has us wondering whether maybe something is about to happen for once. The FDA has scheduled a PCAC meeting for July 23-24 to consider whether to add several peptides to the 503A bulks list, which, in theory, would open the door for state-licensed compounding pharmacies to produce them legally.

https://bit.ly/3QjUyLi

https://bit.ly/4mFdU9H

But before anyone gets too excited, it’s important to note what this actually means – and what it doesn’t.

As APC’s Scott Brunner noted on LinkedIn last week, a shoe has dropped, but only one. The PCAC can recommend adding the named substances to the approved list, but the FDA isn't obligated to follow that recommendation. Even if it does, formal notice-and-comment rulemaking would still be required – a protracted process, unless the agency opts for enforcement discretion in the interim.

https://bit.ly/4tgmPAW

More importantly, even if everything goes right, there's still the supply chain problem. Pharmaceutical-grade API for most of these peptides doesn't currently exist at scale, because there's been no market incentive to develop it. A regulatory green light without a reliable API supply puts compounding pharmacies in an impossible position.

APC supports adding certain peptides to the approved list. The gray and black markets supplying patients right now pose real public health risks, and compounded peptides prepared by state-licensed pharmacies in sterile, USP-compliant environments are meaningfully safer than what's currently available. But how and when FDA acts matters just as much as whether it acts.

So will peptides be coming to a compounding pharmacy near you? We'll find out this summer…maybe.

Map shows status of restrictive compounding legislation in states as of April 15.CaliforniaAB 1990 cleared the Business ...
04/20/2026

Map shows status of restrictive compounding legislation in states as of April 15.

California

AB 1990 cleared the Business & Professions Committee on April 14 with a “do pass as amended” vote, advancing it to the Committee on Privacy and Consumer Protection, where it has a hearing scheduled for April 21. APC Board Vice President Peter Koshland testified in Sacramento this week in opposition, pushing back on misinformation and keeping the discussion grounded in real-world impact. We’re grateful for his time and advocacy.

The bill would restrict compounding of GLP-1 medications in ways we’ve seen attempted in other states this year, and this fight isn’t over. If you’re based in California or serve patients or prescribers there, there’s still time to make your voice heard before the April 21 hearing. Send a message to your Assembly member urging them to oppose AB 1990 – it takes just 30 seconds.

https://bit.ly/4tQQ90S

Kentucky

The Kentucky General Assembly adjourned its 2026 session this week and HB 729 died with it. The bill was aimed at unlicensed entities operating outside the regulated pharmacy system more than at legitimate compounding pharmacies. It applied broadly to all compounded drugs, not just GLP-1s, and would have introduced new permitting requirements, expanded inspection authority, and criminal penalties for certain compounding violations. APC is seeking a few amendments, and we’re hopeful we can find a way to support it when it returns next session.

He’s here, there, and everywhere. Thanks to a grant from the Pharmacy Compounding Foundation, APC’s Scott Brunner was in...
04/17/2026

He’s here, there, and everywhere. Thanks to a grant from the Pharmacy Compounding Foundation, APC’s Scott Brunner was in Columbus last week to present at the Ohio Pharmacists Association’s annual conference. His topic? How GLP-1s Have Changed Compounding. This weekend, thanks to another of those grants, he’ll be in chilly Minot, North Dakota to present on A Pharmacy Compounding Public Policy Update. (Note to Scott: Pack a coat.)

FDA wants more teeth on drug advertising. In its budget request to Congress, the FDA is asking for new authority to declare drugs "misbranded" based on misleading direct-to-consumer advertising — including compounded drugs. The agency wants to be able to act against ads that overstate efficacy, imply broader FDA approval than exists, or fail to clearly disclose that a compounded product has not been reviewed for safety, effectiveness, or quality. The ask isn't surprising given the agency's recent marketing crackdown on telehealth platforms, but turning that enforcement posture into statutory authority would be a meaningful escalation.

Could compounders fill the insulin detemir void? A new citizen petition asks the FDA to declare insulin detemir — the drug formerly marketed by Novo Nordisk as Levemir before it was discontinued — a medically necessary drug in shortage and to permit outsourcing facilities to compound it. There's a legal wrinkle worth noting: compounding pharmacies are generally not permitted to compound biologics under federal law. But the FDA has exercised enforcement discretion on that front before, which makes this one worth keeping an eye on.

A skeptical take on the peptide push. This week, ProPublica published a deep dive into the FDA’s potential reversal on peptides. The piece centers on a core tension: RFK Jr. has called the 2023 decision to categorize 19 peptides as unsafe “illegal,” arguing the agency has no safety signal to justify the move. Three former FDA officials pushed back on the characterization, saying the decision was well-documented and supported by real safety concerns. While the article acknowledges a regulated compounding pathway would be meaningfully safer than the current gray market, it doesn’t fully embrace the argument either. It’s a useful snapshot of where the debate stands and a reminder that however this plays out, proponents will need to make a credible case on safety, not just access.

Read more at https://bit.ly/4vCgKjO

Compliance is the topic, Philly is the townAPC's Scott Brunner and Tenille Davis will be speaking at Informa Connect's C...
04/16/2026

Compliance is the topic, Philly is the town

APC's Scott Brunner and Tenille Davis will be speaking at Informa Connect's Compounding Pharmacy Compliance 2026 conference on June 9-10 — and with registration deadline savings on the table, now is a good time to lock in your spot. The event brings together compounding professionals, industry leaders, and regulators for two days of real talk on compliance challenges, quality standards, and where the industry is headed. APC members can register with a special code for 15% off — and if you register by April 17, you can save an additional $300. Contact info@a4pc.org to recieve your disount today.

Address

100 Daingerfield Road, Ste 100
Alexandria, VA
22314

Telephone

+12819338400

Website

Alerts

Be the first to know and let us send you an email when Alliance for Pharmacy Compounding posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share